Search results
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Benzinga via Yahoo Finance· 2 days agoGrowth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 2 days agoBristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus...
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks· 3 days agoWhile the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Zacks via Yahoo Finance· 5 days agoBoth the Zacks Consensus Estimate and our model estimate for Opdivo’s sales are pegged at $2.3...
Bristol Myers to cut 6% of workforce, trim drug pipeline
BioPharma Dive via Yahoo Finance· 3 days agoThe company has discontinued 12 programs, including a successor version of its immunotherapy Yervoy,...
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks via Yahoo Finance· 3 days agoBristol Myers’ revenues in the first quarter of 2024 are likely to have been boosted by the sales...
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoWe've seen real strength across key brands, including Eliquis, Opdualag, Reblozyl, Yervoy and...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024
FierceBiotech· 3 days agoBristol Myers Squibb is the latest large pharma to wield the restructuring ax, with plans to cut $1.5 billion in costs by the end of 2025, including laying off more than 2,000 employees. The ...